"Paclitaxel" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
| Descriptor ID |
D017239
|
| MeSH Number(s) |
D02.455.426.392.368.242.888.777 D02.455.849.291.850.777
|
| Concept/Terms |
Taxol- Taxol
- Taxol A
- Bris Taxol
- Taxol, Bris
|
Below are MeSH descriptors whose meaning is more general than "Paclitaxel".
Below are MeSH descriptors whose meaning is more specific than "Paclitaxel".
This graph shows the total number of publications written about "Paclitaxel" by people in this website by year, and whether "Paclitaxel" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 4 | 2 | 6 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 1 | 1 |
| 1999 | 3 | 1 | 4 |
| 2000 | 0 | 6 | 6 |
| 2001 | 1 | 1 | 2 |
| 2002 | 0 | 3 | 3 |
| 2003 | 3 | 1 | 4 |
| 2004 | 2 | 2 | 4 |
| 2005 | 2 | 2 | 4 |
| 2006 | 2 | 2 | 4 |
| 2007 | 6 | 5 | 11 |
| 2008 | 5 | 4 | 9 |
| 2009 | 4 | 3 | 7 |
| 2010 | 2 | 5 | 7 |
| 2011 | 4 | 0 | 4 |
| 2012 | 5 | 2 | 7 |
| 2013 | 2 | 2 | 4 |
| 2014 | 5 | 4 | 9 |
| 2015 | 3 | 2 | 5 |
| 2016 | 2 | 2 | 4 |
| 2017 | 2 | 3 | 5 |
| 2019 | 1 | 3 | 4 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Paclitaxel" by people in Profiles.
-
Phase II Clinical and Translational Study of Everolimus ? Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma. Oncologist. 2022 06 08; 27(6):432-e452.
-
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2022 02; 23(2):259-269.
-
The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer. Breast Cancer Res. 2021 06 12; 23(1):65.
-
Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease. JACC Cardiovasc Interv. 2019 12 23; 12(24):2515-2524.
-
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol. 2019 10; 20(10):1360-1369.
-
Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer. Lung Cancer. 2019 08; 134:167-173.
-
Structural insight into substrate and inhibitor discrimination by human P-glycoprotein. Science. 2019 02 15; 363(6428):753-756.
-
Paclitaxel-loaded folate-coated long circulating and pH-sensitive liposomes as a potential drug delivery system: A biodistribution study. Biomed Pharmacother. 2018 Jan; 97:489-495.
-
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017 Oct 07; 390(10103):1654-1663.
-
Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation. Oncotarget. 2017 Apr 25; 8(17):28939-28958.